The laboratory of Dr. David Rickman at Weill Cornell Medicine (WCM) in New York City is seeking 2 highly motivated postdoctoral fellows with experience in transcription factor biology or epigenomic modifiers. The fellows will work on 2 different projects, one addressing a fundamental cancer biology question and the other one using a translational approach. Both projects build on previous work from the Rickman lab (Cancer Discovery, 2011 and Cancer Cell, 2016) characterizing the role of N-Myc and interacting cofactors in driving castrate resistant prostate cancer and neuroendocrine prostate cancer (NEPC).
One fellow will lead an NIH-funded project to characterize the role of drivers of lineage plasticity and epigenetic reprogramming in prostate cancer therapy resistance. This is also in the context of a Weill Cornell Medicine Prostate Cancer SPORE grant. For these goals, the fellow will use genome-wide molecular techniques (e.g. RNA-seq, ChIP-seq, ATAC-seq) in combination with available models described above. He/she will perform all pertinent validation experiments. Highly motivated applicants must possess a PhD or equivalent and research experience in epigenetic, cell and molecular biology and cancer biology. Having computational experience for high-throughput data analyses is highly valued. This project will involve a broad network of interactions with computational, clinical and basic researchers at WCM and other major academic institutions. Long-term goals for this fellow will be to develop as a prostate cancer basic scientist.
The other fellow will lead a pharma-funded project that focuses on the development of novel therapeutic strategies for NEPC. This project will involve interactions with physicians, physician/scientists at WCM, the Dana Farber Cancer Center (Boston) and pharmaceutical companies. This project will leverage a new inducible genetically engineered mouse (GEM) model that will allow for temporal control of N-Myc expression and lineage tracing. Studies will be performed in combination with available in vitro, ex vivo and in vivo models (e.g. cell lines, human and mouse prostate cancer organoids, patient derived xenografts and GEM models). Highly motivated applicants must possess a PhD or equivalent and research experience with in vitro and in vivo drug dosing, tracking tumor volume, tail vein injection and in vivo imaging. Long-term goals for this fellow will be to develop as a prostate cancer translational scientist.
Other qualifications and requirements include a strong record of scientific productivity with publications as first author in internationally renowned journals, critical thinking and organizational skills with supervisory experience.
The individual should have experience with working in teams, as well as an ability to work independently.
Salary and benefits commensurate with experience and NIH guidelines.
Applicants who are interested in this position should e-mail:
1) Statement of research interests and career goals
2) Curriculum Vitae including bibliography
3) Names and contact information for two or three references
David S. Rickman, Ph.D.
Weill Cornell Medicine
Department of Pathology and Laboratory Medicine
Weill Cornell Medical College
1300 York Avenue, Room C-610D
New York, NY 10021
T: 212 -746-9171